Novavax, Inc. (NVAX)
| Market Cap | 1.21B |
| Revenue (ttm) | 1.08B |
| Net Income (ttm) | 422.82M |
| Shares Out | 162.42M |
| EPS (ttm) | 2.54 |
| PE Ratio | 2.94 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,397,755 |
| Open | 7.56 |
| Previous Close | 7.58 |
| Day's Range | 7.44 - 7.79 |
| 52-Week Range | 5.01 - 15.22 |
| Beta | 2.50 |
| Analysts | Buy |
| Price Target | 14.29 (+91.3%) |
| Earnings Date | Aug 6, 2025 |
About NVAX
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]
Financial Performance
In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for NVAX stock is "Buy." The 12-month stock price target is $14.29, which is an increase of 91.30% from the latest price.
News
Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season GAITHERSBURG, Md. , Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX...
Novavax Announces Convertible Debt Refinancing
Refinancing extends maturity of most existing debt with improved terms $225 million of convertible notes due in 2031 issued, including a ~$175 million exchange for the retirement of existing convertib...
Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO & ...
Novavax beats quarterly revenue estimates on milestone payment
Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment related to U.S. approval of its COVID-19 vaccine in May.
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
Total revenue of $239 million in the second quarter of 2025 Received FDA BLA approval for Nuvaxovid™, the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.; approval trig...
Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025
GAITHERSBURG, Md. , July 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m.
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates
Novavax, Inc. NVAX on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate.
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single int...
Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Novavax, Inc. (NASDAQ:NVAX) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacob...
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study
Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune responses in some patients tested in a late-stage study, the company said on Wednesday.
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
Both vaccine candidates induced robust immune responses across all antigens tested No new safety signals were observed and both vaccine candidates were well tolerated consistent with past trials Novav...
Vaccine actions and policy positions under US Health Secretary Kennedy
U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.
Novavax to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md. , May 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conferences: Jefferies Global Healthcare Confe...
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the o...
Healthy Returns: Novavax scores narrower Covid vaccine approval after delay
The FDA approved Novavax's Covid-19 vaccine but with unusual restrictions.
Top Stock Movers Now: Tesla, AutoZone, Novavax, and More
U.S. equities were down at midday, while the yield on the 10-year Treasury jumped, as the market reacted to Moody's downgrading the U.S. debt rating. The Dow Jones Industrial Average, S&P 500, and Nas...
Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.
Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with rival vaccine makers.
Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine
Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine from the U.S. health regulator, albeit with new conditions.
U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine
Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S. Biologics License Application approval triggers $175 million Sanofi milestone payment, with additional...
FDA approves Novavax COVID vaccine with new conditions
The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on individuals who would be able to receive the vaccine.
Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript)
Novavax, Inc. (NASDAQ:NVAX) BofA Securities 2025 Health Care Conference May 14, 2025 6:00 PM ET Company Participants John Jacobs - President and CEO Jim Kelly - CFO Ruxandra Draghia-Akli - EVP, Head,...
Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat
Initiate coverage on Novavax with a Buy rating; Q1 2025 marks an inflection point with $519M net income and raised revenue guidance to $975M-$1.025B. Novavax's Q1 2025 revenue surged to $667M, driven ...
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
On Thursday, Novavax Inc. NVAX reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million.